Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf; David Siegel; Hartmut Goldschmidt; Katharine Hazell; Priscille M. Bourquelot; Bourras R. Bengoudifa; Jeffrey Matous; Ravi Vij; Margarida De Magalhaes-Silverman; Rafat Abonour; Kenneth C. Anderson; Sagar Lonial

Article

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Leukemia and Lymphoma

DOI: 10.3109/10428194.2012.661175

117Citations

62Readers

Get full text

Cite

CITATION STYLE

APA

Wolf, J. L., Siegel, D., Goldschmidt, H., Hazell, K., Bourquelot, P. M., Bengoudifa, B. R., … Lonial, S. (2012, September). Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia and Lymphoma. https://doi.org/10.3109/10428194.2012.661175

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Cite

Register to see more suggestions